Drug Database
YE

yellow fever vaccine (Arilvax)

✓ Approved

Novartis AG · Vaccine · Vaccine

What is yellow fever vaccine?

yellow fever vaccine is a vaccine developed by Novartis AG. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesArilvax
CompanyNovartis AG
Drug ClassVaccine, Large Molecules
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Novartis AG

Therapeutic Indications

yellow fever vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsYellow fever✓ Approved

Related Research Articles

PubMedJournal of general and family medicine2026-11-11

Clinical Practice Profiles Among Japanese General Medicine Physicians in Treating Adult Patients With Periodic Fever Associated With Autoinflammatory Diseases: A Nationwide Cross-Sectional Survey.

Takahashi Noriyuki N, Inage Eisuke E, Tanaka Seiji S, Hiyoshi Yusuke Y et al.

In Japan, general medicine physicians (GMPs) may treat adult patients who have periodic fever associated with autoinflammatory diseases. However, little is known about the status of practice among GMPs in treating these patients. Although prescribing cimetidine is a therapeutic option for periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome, GMPs' prescribing behavior is uncertain. We aimed to investigate: (1) practice among GMPs in treating adult patients with periodic fever associated with autoinflammatory diseases; (2) prescription of cimetidine by GMPs for patients with periodic fever associated with autoinflammatory diseases in general. A nationwide cross-sectional study was conducted using an anonymous online questionnaire in May and June 2025. Physicians who were affiliated with three general medicine-related academic societies in Japan were selected. The questionnaire examined whether respondents had experience treating patients with periodic fever associated with autoinflammatory diseases, current cimetidine prescription practices, the number of patients by age, and respondents' characteristics. Descriptive statistical analysis was performed. We analyzed data from 247 respondents. Of these, 181 respondents reported having experience treating periodic fever. Among respondents, 159 (87.8%) had experience treating familial Mediterranean fever, and more than half had experience treating Behçet's disease or PFAPA syndrome; 31 (17.1%) were currently prescribing cimetidine to 44 patients. Among patients, 32 (72.7%) were aged between 18 and 39 years. Colchicine and corticosteroids were the main concomitant and alternative medications related to cimetidine. The current results describe clinical practice profiles among Japanese GMPs treating adult patients with periodic fever associated with autoinflammatory diseases (250/250 words).

PMID 43011523
Read full article →
PubMedInfectious diseases of poverty2026-11-11

The rapidly growing burden of dengue fever in China from 2005 to 2024: spatiotemporal patterns and age-sex-specific disparities in incidence and disability-adjusted life years.

Li Sihan S, Zhai Hongrui H, Xu Caihong C, Huang Meilan M et al.

Dengue fever has transitioned from a sporadic imported infection to an established domestic threat in China, challenging the conventional view of its non-endemic status. Understanding its evolving epidemiological landscape over the past two decades is critical for evidence-based intervention planning. We analyzed national notifiable dengue surveillance data from 2005 to 2024. Temporal trends were assessed using Joinpoint regression to estimate average annual percent changes (AAPC) in incidence, stratified by age, sex, and province, with particular focus on Guangdong and Yunnan. Spatial heterogeneity was characterized through standardized provincial incidence mapping. Disease burden was quantified using disability-adjusted life years (DALYs), incorporating years of life lost and years lived with disability, based on locally derived severity distributions and disability weights. A total of 138,885 cases and 14 deaths were reported. Annual case counts rose sharply from 40 to 24,278, with major epidemic peaks in 2014, 2019, 2023, and 2024. The age-standardized incidence increased significantly (AAPC: + 30.1%). Adults aged 25-49 years constituted 49.2% of all cases, yet the steepest relative increases occurred among children aged 0-9 years (male AAPC + 32.7%, female + 35.4%) and adults aged ≥ 70 years (male + 43.3%, female + 39.6%). High-risk category I regions accounted for 87.1% of the national burden, though other low-risk regions exhibited accelerating incidence among specific adult male subgroups. Total DALYs reached 2206.9 person-years (age-standardized rate: 0.0744 per million), predominantly driven by YLD and concentrated in the working-age population (79.5%). Dengue in China has entered a phase of rapid burden escalation with widening demographic and geographic reach. While the working-age population bears the largest absolute burden, children and older adults face the fastest-rising risk. These findings underscore the urgency of transitioning from reactive outbreak response to precision public health, integrating age-targeted interventions, regionally stratified surveillance, and serological monitoring within a One Health framework to inform future vaccine deployment.

PMID 43010038
Read full article →
PubMedFrontiers in veterinary science2026-11-11

Comparison of the pathogenicity of a Taiwan lineage 1 NADC30/34-like recombinant and a lineage 3 Betaarterivirus suid 2 in pigs.

Lai Yi-Fang YF, Lin Chao-Nan CN, Chiou Ming-Tang MT, Chang Yen-Chen YC et al.

Porcine reproductive and respiratory syndrome virus 2 (PRRSV-2; Betaarterivirus suid 2) causes porcine reproductive and respiratory syndrome, leading to severe economic losses in the global swine industry. Lineage 1 (L1) PRRSV-2 has emerged and become increasingly prevalent in North America and Asia. This study compared the pathogenic characteristics of a Taiwan NADC30/34-like L1 recombinant and a lineage 3 (L3) PRRSV-2 strain and evaluated their suitability for establishing an experimental infection model in growing pigs. Ten-week-old pigs were inoculated with either the NADC30/34-like L1 NPUST-107-844/2018 strain or the L3 SW2018001-YL strain via concurrent intranasal and intramuscular routes. Pigs inoculated with the L1 strain exhibited higher body temperatures and a greater frequency of fever during the early post-inoculation period than those inoculated with the L3 strain. However, no significant differences were observed between the groups in peak viremia, lung pathological scores, or plasma cytokine concentrations. These results indicate that the Taiwan L1 strain induced a more pronounced early febrile response but produced virological, pulmonary pathological, and systemic cytokine responses comparable to those induced by the Taiwan L3 strain. Collectively, these findings highlight the pathogenic diversity of circulating PRRSV-2 strains in Taiwan and for future experimental studies, including investigations of disease pathogenesis, therapeutic interventions, and vaccine development.

PMID 43011046
Read full article →
PubMedNPJ vaccines2026-11-11

A structure-guided trivalent subunit vaccine confers maternal protection to neonatal piglets against PEDV and PDCoV.

Liu Jia J, Chen Longping L, Li Dan D, Wang Zhuo Z et al.

Antigenic divergence among porcine epidemic diarrhea virus (PEDV) genotypes and porcine deltacoronavirus (PDCoV) limits the cross-protection provided by current commercial vaccines. Here, employing a structure-guided antigen design strategy, we developed a trivalent subunit vaccine concurrently targeting PEDV G2a, PEDV G2b, and PDCoV. The vaccine antigen set comprises optimized spike ectodomain antigens, featuring stabilizing mutations, a heptad repeat 2 (HR2) deletion, a fused neutralizing epitope, and a flagellin adjuvant fused to the N-terminus. Formulated with MF59+CpG adjuvants, this trivalent vaccine elicited robust PEDV- and PDCoV-specific neutralizing antibody responses and Th1/Th2-associated cellular immune responses characterized by IFN-γ, IL-2, and IL-4 production in mice. Immunization of pregnant sows with 300 μg dose induced high-titer IgG, IgA, and colostral secretory IgA (SIgA) against all three target viruses. Although neutralizing antibody titers were comparable between the 100 μg and 300 μg dose groups, the 300 μg group showed higher and more persistent levels of colostral binding IgG and SIgA. Following maternal immunization, piglets that acquired maternal antibodies through colostrum exhibited reduced clinical diarrhea, lower fecal viral RNA shedding, and less severe intestinal lesions after challenge with PEDV G2a, PEDV G2b, or PDCoV. These findings support this structure-guided trivalent subunit vaccine as a promising candidate for maternal immunization against co-circulating porcine enteric coronaviruses.

PMID 43009510
Read full article →
PubMedJournal of public health in Africa2026-11-11

An outbreak investigation of a large dengue fever outbreak in Somaliland, 2023-2024.

Asad Hibo H, Ali Amal A, Hashi Ahmed A, Hirsi Idhil I et al.

Somaliland experienced a large dengue fever outbreak between 2023 and 2024. National laboratory surveillance identified 4971 clinically suspected cases that underwent testing ('tested probable cases'), of which 1703 were confirmed using rapid diagnostic tests. Three deaths were reported. Cases spanned five regions of Somaliland, with 74% in Marodijeh. As surveillance data were restricted to public-sector facilities, these findings represent a lower-bound estimate of true dengue transmission. We highlight the utility of the new laboratory surveillance and the need for mitigating dengue risks amid climatic fluctuations.

PMID 43011431
Read full article →
PubMedHealth communication2026-11-11

Spiritual Health Locus of Control and COVID-19 Booster Intentions Among Hispanic Americans: A Culturally Grounded Extension of the Extended Parallel Process Model.

Kim Joon J, Jun Jungmi J, Zambrano Rodriguez Viviana Carolina VC

Declining uptake of COVID-19 boosters poses significant public health concerns. Hispanic Americans, who have experienced disproportionate pandemic impacts, report lower uptake of updated boosters than non-Hispanic White adults, partly attributable to vaccine hesitancy. Although religiosity plays a central role in Hispanic communities, little is known about how spiritually grounded beliefs shape cognitive and emotional responses to vaccination. This study integrates the extended parallel process model (EPPM) with spiritual health locus of control (SHLOC) to examine how exposure to faith-based and governmental vaccine information influences booster intention through spiritually grounded efficacy appraisals. Using an online survey of Hispanic American adults (N = 349), we tested a structural equation model linking SHLOC, perceived threat, efficacy beliefs, fear, and vaccination intentions. Results indicated that active SHLOC, reflecting beliefs in divine partnership in health, increased response efficacy and indirectly promoted booster intention and vaccine advocacy, whereas passive SHLOC, reflecting divine determinism, reduced self-efficacy and indirectly discouraged booster intention. Perceived threat was positively associated with fear, and efficacy beliefs emerged as the strongest predictors of booster intention. Mediation analyses supported serial pathways from message exposure to SHLOC to efficacy to intention, identifying spiritually grounded control beliefs as a culturally embedded mechanism in vaccine decision making. Findings suggest that faith-based engagement can function as either a protective or risk communication channel, depending on whether messages reinforce divine partnership or determinism. The study advances EPPM by identifying SHLOC as a culturally grounded antecedent to efficacy appraisal and offers implications for culturally responsive vaccine communication in Hispanic communities.

PMID 43012739
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about yellow fever vaccine